SAN DIEGO--(BUSINESS WIRE)--Halozyme Therapeutics, Inc. (Nasdaq:HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced H. Michael Shepard, Ph.D., has joined the company as vice president, discovery research. Dr. Shepard is a recipient of numerous biotechnology patents and scientific awards for his contributions to the development of innovative therapies.
